These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 37603070)

  • 1. Retrospective real-world analysis of adherence and persistence to lipid-lowering therapy in Germany.
    Koenig W; Lorenz ES; Beier L; Gouni-Berthold I
    Clin Res Cardiol; 2024 Jun; 113(6):812-821. PubMed ID: 37603070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential Adherence to Free and Single-Pill Combination of Rosuvastatin/Ezetimibe: Findings from a Real-World Analysis in Italy.
    Perez de Isla L; Liberopoulos E; Dovizio M; Veronesi C; Degli Esposti L; Zambon A
    Adv Ther; 2024 Aug; 41(8):3407-3418. PubMed ID: 38963586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol ≥190 mg/dL: Insights From the National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence Registry.
    Virani SS; Kennedy KF; Akeroyd JM; Morris PB; Bittner VA; Masoudi FA; Stone NJ; Petersen LA; Ballantyne CM
    Circ Cardiovasc Qual Outcomes; 2018 May; 11(5):e004652. PubMed ID: 29748356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes.
    Khan SU; Talluri S; Riaz H; Rahman H; Nasir F; Bin Riaz I; Sattur S; Ahmed H; Kaluski E; Krasuski R
    Eur J Prev Cardiol; 2018 May; 25(8):844-853. PubMed ID: 29569492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease.
    Cannon CP; Khan I; Klimchak AC; Reynolds MR; Sanchez RJ; Sasiela WJ
    JAMA Cardiol; 2017 Sep; 2(9):959-966. PubMed ID: 28768335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical characteristics and treatment patterns in patients with atherosclerotic cardiovascular disease with hypercholesterolemia: a retrospective analysis of a large US real-world database cohort.
    Lahoz R; Seshagiri D; Electricwala B; Achouba A; Ding Y; Heo JH; Cristino J; Studer R
    Curr Med Res Opin; 2024 Jan; 40(1):15-25. PubMed ID: 37941428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations.
    Hao Q; Aertgeerts B; Guyatt G; Bekkering GE; Vandvik PO; Khan SU; Rodondi N; Jackson R; Reny JL; Al Ansary L; Van Driel M; Assendelft WJJ; Agoritsas T; Spencer F; Siemieniuk RAC; Lytvyn L; Heen AF; Zhao Q; Riaz IB; Ramaekers D; Okwen PM; Zhu Y; Dawson A; Ovidiu MC; Vanbrabant W; Li S; Delvaux N
    BMJ; 2022 May; 377():e069066. PubMed ID: 35508320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PCSK9 Inhibitors' New Users: Analysis of Prescription Patterns and Patients' Characteristics from an Italian Real-world Study.
    Piccinni C; Antonazzo IC; Maggioni AP; Pedrini A; Calabria S; Ronconi G; Dondi L; Martini N; Roberto G; Sampietro T; Sbrana F; Pino BD; Bigazzi F; Surdo GL; Volpi E; Biagini S; Gini R
    Clin Drug Investig; 2020 Feb; 40(2):173-181. PubMed ID: 31797311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The therapeutic management of South African dyslipidaemic patients at very high cardiovascular risk (CARDIO TRACK): a cross-sectional study.
    Blom DJ; Ranjith N; Joshi P; Naidoo P; van Tonder A; Musa MG; Joshi S; Leisegang R; Trokis JS; Makan H; Raal FJ
    Cardiovasc J Afr; 2020; 31(5):245-251. PubMed ID: 33151240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics and Outcomes of Patients Treated With Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (The Mayo Clinic Experience).
    Oren O; Kludtke EL; Kopecky SL
    Am J Cardiol; 2019 Dec; 124(11):1669-1673. PubMed ID: 31740018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medication Adherence/Persistence and Demographics of Japanese Dyslipidemia Patients on Statin-Ezetimibe as a Separate Pill Combination Lipid-Lowering Therapy　- An Observational Pharmacy Claims Database Study.
    Umeda T; Hayashi A; Fujimoto G; Piao Y; Matsui N; Tokita S
    Circ J; 2019 Jul; 83(8):1689-1697. PubMed ID: 31281135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-PCSK9 antibodies for hypercholesterolaemia: Overview of clinical data and implications for primary care.
    Descamps OS; Fraass U; Dent R; März W; Gouni-Berthold I
    Int J Clin Pract; 2017 Aug; 71(8):. PubMed ID: 28750477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simulation of lipid-lowering therapy (LLT) intensification in very high-risk patients with atherosclerotic cardiovascular disease.
    Gu J; Sanchez RJ; Chauhan A; Fazio S; Rosenson RS
    J Clin Lipidol; 2022; 16(6):901-905. PubMed ID: 36319536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world data on metabolic effects of PCSK9 inhibitors in a tertiary care center in patients with and without diabetes mellitus.
    Fischer LT; Hochfellner DA; Knoll L; Pöttler T; Mader JK; Aberer F
    Cardiovasc Diabetol; 2021 Apr; 20(1):89. PubMed ID: 33894772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cholesterol lowering therapies and achievement of targets for primary and secondary cardiovascular prevention in type 2 diabetes: unmet needs in a large population of outpatients at specialist clinics.
    Morieri ML; Avogaro A; Fadini GP;
    Cardiovasc Diabetol; 2020 Nov; 19(1):190. PubMed ID: 33172454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of a Combined Measure of Adherence and Treatment Intensity With Cardiovascular Outcomes in Patients With Atherosclerosis or Other Cardiovascular Risk Factors Treated With Statins and/or Ezetimibe.
    Khunti K; Danese MD; Kutikova L; Catterick D; Sorio-Vilela F; Gleeson M; Kondapally Seshasai SR; Brownrigg J; Ray KK
    JAMA Netw Open; 2018 Dec; 1(8):e185554. PubMed ID: 30646277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving statin treatment strategies to reduce LDL-cholesterol: factors associated with targets' attainment in subjects with and without type 2 diabetes.
    Morieri ML; Perrone V; Veronesi C; Degli Esposti L; Andretta M; Plebani M; Fadini GP; Vigili de Kreutzenberg S; Avogaro A
    Cardiovasc Diabetol; 2021 Jul; 20(1):144. PubMed ID: 34271920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adherence To Lipid-Lowering Therapy In Patients With Coronary Heart Disease From The State Of Saxony-Anhalt, Germany.
    Waßmuth S; Rohe K; Noack F; Noutsias M; Treede H; Schlitt A
    Vasc Health Risk Manag; 2019; 15():477-483. PubMed ID: 31802881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simulation of the Impact of Statin Intolerance on the Need for Ezetimibe and/or Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor for Meeting Low-Density Lipoprotein Cholesterol Goals in a Population With Atherosclerotic Cardiovascular Disease.
    Cannon CP; Sanchez RJ; Klimchak AC; Khan I; Sasiela WJ; Reynolds MR; Rosenson RS
    Am J Cardiol; 2019 Apr; 123(8):1202-1207. PubMed ID: 30736965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors and Cardiovascular Risk: Does a Further Analysis of the Fourier Trial Suggest Changes in the Target of Lipid Lowering Therapy?
    Cervelli N; Tocci G; Ferri C
    High Blood Press Cardiovasc Prev; 2018 Mar; 25(1):5-7. PubMed ID: 29305812
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.